Aspen Aerogels, Inc. filings document the company's aerogel technology business, operating results and material corporate events. Recent Forms 8-K cover quarterly and annual financial results, Regulation FD disclosures, business developments, manufacturing-facility updates, and amendments to the MidCap Loan Facility and related credit-party obligations.
The filing record also includes proxy materials describing governance, board and compensation matters, executive employment arrangements, equity awards and shareholder voting items. Aspen's disclosures connect its capital structure and credit covenants with operations in Energy Industrial and Thermal Barrier products, including PyroThin, Cryogel and Pyrogel applications.
Daniel Santhosh P, the Chief Accounting Officer of Aspen Aerogels, filed a Form 4 reporting the sale of company common stock in two transactions on 08/12/2025 and 08/13/2025. On 08/12/2025 he sold 4,410 shares in multiple trades at prices ranging about $7.31–$7.32, and the report shows 19,879 shares beneficially owned following that transaction. On 08/13/2025 he sold 2,000 shares at $7.54, with 17,879 listed as beneficially owned following that sale.
The filing notes that the 17,879 shares represent Restricted Stock Units. No derivative securities are reported. A Power of Attorney is attached as Exhibit 24 and the form is signed by an attorney-in-fact, Stephanie Pittman, on 08/13/2025. The report is limited to the disclosed share counts, transaction dates, and prices in the form.
Aspen Aerogels, Inc. (ASPN) has filed a Form 144 reporting a proposed sale of 4,410 common shares through Morgan Stanley Smith Barney LLC on the New York Stock Exchange with an aggregate market value of $32,251.65 and an approximate sale date of 08/12/2025. The filing identifies the shares as common stock and lists total shares outstanding as 82,360,491, indicating the sale is a small, specific disposition of restricted shares previously acquired.
The securities to be sold were acquired as restricted stock on two dates: 3/5/2025 (796 shares) and 9/13/2024 (3,614 shares). The filer reports no sales of the issuer's securities in the past three months. The notice includes the standard insider representation regarding absence of undisclosed material adverse information.